Cancer clinical trials in the region Bourgogne-Franche-Comté

202 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06072781

[RAMP 301] Étude de l'association avutométinib (VS-6766) + defactinib (VS-6063) dans le cancer de l'ovaire séreux de bas grade récidivant

Epithelial ovarian cancer Serous low grade carcinoma (LGSOC) Locally Advanced Metastatic 1 2 3 or more

Systemic Treatment-Naive

5 recruiting sites

Verastem

Phase 3 Lung cancer #NCT06345729 #2023-507776-42-00

Étude de MK-1084 plus PEMBROLIZUMAB chez des participants atteints d'un cancer du poumon non à petites cellules métastatique KRAS G12C muté avec PD-L1 TPS ≥ 50 %

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive

7 recruiting sites

Merck Sharp & Dohme LLC

Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05445778 #2022-501606-35-01

[GLORIOSA] Mirvetuximab soravatsine associé au bévacizumab versus bévacizumab seul en traitement d'entretien du cancer épithélial de l'ovaire, des trompes de Fallope ou du péritoine sensible au platine

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Serous high grade carcinoma (HGSOC) Greater than or equal to 75% 1 Recurrence 6 months or more after platinum treatme... Chemotherapy Chemotherapy

Systemic Treatment-Naive Systemic Treatment-Naive

1 recruiting site

Abbvie

Phase 3 Breast cancer #NCT06982521 #2025-523083-21-00

Étude de phase 3 comparant RLY-2608 + fulvestrant à capivasertib + fulvestrant dans le traitement du cancer du sein localement avancé ou métastatique porteur de la mutation PIK3CA HR+/HER2-

HER2 Negative HR Positive Locally Advanced Metastatic PIK3CA None 1 2 Targeted therapy Systemic Treatment-Naive Targeted therapy Hormone therapy

AKT PTEN Immunotherapy Antibody Drug Conjugates (ADC) Immunotherapy Antibody Drug Conjugates (ADC)

8 recruiting sites

Relay Therapeutics, Inc.

Phase 3 Endometrial cancer #NCT06340568 #2023-507525-42-00

Étude clinique des effets anticancéreux d'un traitement expérimental ou d'une chimiothérapie chez des patientes atteintes d'un cancer de l'utérus récidivant

Cohorte 1 et 2

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Locally Advanced Metastatic HER2 None 1 Immunotherapy Chemotherapy Systemic Treatment-Naive Immunotherapy Chemotherapy

Antibody Drug Conjugates (ADC) Antibody Drug Conjugates (ADC)

8 recruiting sites

BioNTech SE

Phase 3 Endometrial cancer #NCT06712472 #2023-503886-44-00

[RAINBO-RED] Essai randomisé de phase III comparant l'OLAPARIB d'entretien à l'observation après chimioradiothérapie adjuvante pour le cancer de l'endomètre P53abn

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Stage I Stage II Stage III Localized Locally Advanced TP53 None Surgery Chemotherapy Radiotherapy

MSI/dMMR POLE

14 recruiting sites

Gustave Roussy, Campus du cancer, Grand Paris

Phase 3 Anal cancer #NCT06207981 #2023-505972-32-00

[KANALRAD] Étude évaluant la chimiothérapie d'induction suivie d'une chimioradiothérapie par rapport à la chimioradiothérapie standard pour les carcinomes épidermoïdes de l'anus localement avancés

Locally Advanced

Radiotherapy Radiotherapy

54 recruiting sites

Fédération Francophone de Cancérologie Digestive

Phase 3 Breast cancer #NCT05952557 #2023-504031-41-00

[CAMBRIA-2] Etude sur le traitement endocrinien adjuvant CAMIZESTRANT dans le cancer du sein précoce ER+/HER2-

HER2 Negative HR Positive Localized None Surgery Chemotherapy Radiotherapy Hormone therapy

Systemic Treatment-Naive

22 recruiting sites

AstraZeneca

Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00

MOSUNETUZUMAB - LENALIDOMIDE par rapport aux choix de l'investigateur chez les patients atteints de lymphome de la zone marginale en rechute ou réfractaire

B cell lymphoma Marginal zone lymphoma None > 60 ml/min 50-60 ml/min 30-50 ml/min 1 2 3 or more Targeted therapy Monoclonal antibodies

Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant

23 recruiting sites

The Lymphoma Academic Research Organisation (LYSARC)

Phase 3 Breast cancer #NCT06195709 #2023-506282-66-00

[ECLECTIC] EstroTEP et biomarqueurs circulants pour les patientes atteintes d'un cancer du sein métastatique RH-positif et HER2-négatif

HER2 Negative HR Positive Metastatic 1 Targeted therapy Hormone therapy

Chemotherapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)

10 recruiting sites

Institut Curie